Implementation of the advanced HIV disease package of care using a public health approach: lessons from Nigeria

Nigeria adapted the WHO package of care for Advanced HIV Disease (AHD) in 2020. The package includes CD4 + cell count testing to identify People Living with HIV (PLHIV) with AHD, screening and treatment of opportunistic infections, rapid antiretrovirals (ART) initiation, and intensive adherence foll...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC public health 2024-12, Vol.24 (1), p.3366-14
Hauptverfasser: Eigege, Williams, Agbaji, Oche, Otubu, Nere, Abudiore, Opeyemi, Sowale, Oluwakemi, Levy-Braide, Boma, Inyang, Asari, Rathakrishnan, Dinesh, Amamilo, Ikechukwu, Conroy, James, Lufadeju, Folu, Amole, Carolyn, Wiwa, Owens, Onotu, Dennis, Sanni, Khalil, Nwaokenneya, Peter, Patiko, Mohammed, Ikpeazu, Akudo, Oguche, Stephen, Oladele, Rita, Akanmu, Sulaimon
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nigeria adapted the WHO package of care for Advanced HIV Disease (AHD) in 2020. The package includes CD4 + cell count testing to identify People Living with HIV (PLHIV) with AHD, screening and treatment of opportunistic infections, rapid antiretrovirals (ART) initiation, and intensive adherence follow-up. The national program adopted a phased approach in the rollout of the AHD package of care to learn lessons from a few representative health facilities before scaling up across the country. This study describes the process and lessons learned from the first phase of implementation. This was a prospective observational study, and participants were enrolled between February and September 2021. Healthcare-worker (HCW) capacity was built to implement the AHD package of care. The study population included newly diagnosed PLHIV ≥ 10 years presenting to care in 28 selected facilities across 4 states in Nigeria. Eligible participants received CD4 + cell testing at baseline. Those with CD4 + cell count 
ISSN:1471-2458
1471-2458
DOI:10.1186/s12889-024-20841-x